Development of Prolinol Containing Inhibitors of Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase: Rational Structure-Based Drug Design.
Dianne T KeoughMagdalena PetrováGordon KingMichal KratochvílRadek PohlEva DoleželováAlena ZíkováLuke W GuddatDominik RejmanPublished in: Journal of medicinal chemistry (2024)
Inhibition of hypoxanthine-guanine-xanthine phosphoribosyltransferase activity decreases the pool of 6-oxo and 6-amino purine nucleoside monophosphates required for DNA and RNA synthesis, resulting in a reduction in cell growth. Therefore, inhibitors of this enzyme have potential to control infections, caused by Plasmodium falciparum and Plasmodium vivax , Trypanosoma brucei , Mycobacterium tuberculosis , and Helicobacter pylori . Five compounds synthesized here that contain a purine base covalently linked by a prolinol group to one or two phosphonate groups have K i values ranging from 3 nM to >10 μM, depending on the structure of the inhibitor and the biological origin of the enzyme. X-ray crystal structures show that, on binding, these prolinol-containing inhibitors stimulated the movement of active site loops in the enzyme. Against TBr in cell culture, a prodrug exhibited an EC 50 of 10 μM. Thus, these compounds are excellent candidates for further development as drug leads against infectious diseases as well as being potential anticancer agents.